Patents by Inventor Kazuyoshi Aso
Kazuyoshi Aso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7714009Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A?): wherein X is a carbon and X1 is an oxygen, a sulfur or —NR5—, or formula (A?): wherein X is a nitrogen and R6 is an optionally substituted hydrocarbyl, R1 is an amino substituted by two optionally substituted hydrocarbyl groups, R2 is an phenyl, Y1 is CR3a or a nitrogen, Y2 is CR3b or a nitrogen and Y3 is CR3c or a nitrogen, provided that one or less of Y1, Y2, and Y3 is nitrogen, W is a bond, —(CH2)n-, and Z is a bond, —NR4—, etc.; or a salt thereof or a prodrug thereof.Type: GrantFiled: October 27, 2004Date of Patent: May 11, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Albert Charles Gyorkos, Christopher Peter Corrette, Suk Young Cho, Timothy Mark Turner, Scott Alan Pratt, Kazuyoshi Aso, Masakuni Kori, Michiyo Gyoten
-
Publication number: 20100056515Abstract: There is provided a compound of the formula (I): wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6-membered ring which may be substituted with 1 to 3 C1-6 alkyls; R4 is a hydrogen, a halogen, a hydroxy, a cyano, a C1-6 alkyl or a C1-6 alkoxy; Z is —O—, —S—, —SO—, —SO2—, or —NR5— wherein R5 is a hydrogen or a C1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.Type: ApplicationFiled: October 24, 2007Publication date: March 4, 2010Inventors: Kazuyoshi Aso, Michiyo Mochizuki, Takuto Kojima, Katsumi Kobayashi, Scott Alan Pratt, Albert Charles Gyorkos, Christopher Peter Corrette, Suk Young Cho
-
Publication number: 20100048658Abstract: There is provided a compound of the formula: wherein R1 is an optionally substituted hydrocarbyl, a substituted amino, etc.; R2 is an aromatic group substituted with one or two substituents at the positions adjacent to the position bonded to Z, and said aromatic group may have additional substituent(s); X is —NR3— wherein R3 is a hydrogen, an optionally substituted hydrocarbyl or an acyl, or sulfur; Y1, Y2 and Y3 are an optionally substituted methine or a nitrogen, etc.; and Z is an optionally substituted methylene, provided that carbonyl is excluded; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.Type: ApplicationFiled: December 28, 2007Publication date: February 25, 2010Inventors: Kazuyoshi Aso, Michiyo Mochizuki, Katsumi Kobayashi
-
Publication number: 20090312383Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; R2 is an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or —NR3— (wherein R3 is a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y1, Y2 and Y3 are each an optionally substituted carbon or a nitrogen, provided that one or less of Y1, Y2 and Y3 is nitrogen; and Z is a bond, —CO—, oxygen, sulfur, —SO—, —SO2—, —NR4—, —NR4-alk-, —CONR4— or —NR4CO— (wherein alk is an optionally substituted C1-4 alkylene and R4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.Type: ApplicationFiled: April 26, 2006Publication date: December 17, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kazuyoshi Aso, Michiyo Mochizuki, Albert Charles Gyorkos, Christopher Peter Corrette, Suk Young Cho, Scott Alan Pratt, Christopher Stephen Siedem
-
Publication number: 20090186879Abstract: There is provided a compound of the formula (I?): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y1, Y2 and Y3 is an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.Type: ApplicationFiled: January 21, 2009Publication date: July 23, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kazuyoshi Aso, Katsumi Kobayashi, Takafumi Takai, Takuto Kojima, Kazuyuki Tokumaru, Michiyo Mochizuki, Yasutaka Hoashi
-
Patent number: 7507753Abstract: The present invention provides a compound having melanocortin receptor agonist activity or antagonist activity, which is a novel biaryl compound represented by the formula (I): wherein ring A and ring B are optionally further substituted 6-membered aromatic rings; X is —CONR4—, —SO2NR4—, —CH2NR4— (R4 is a hydrogen atom, an optionally substituted hydrocarbon group, etc.), etc.; Y is a spacer having 1 to 12 atoms, etc.; Z is —CONR6—, —CO— (R6 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), etc.; R1 is an optionally substituted amino group, etc.; R2 is an optionally substituted hydrocarbon group, etc.; R3 is an optionally substituted hydrocarbon group, etc.; and R5 is an optionally substituted hydrocarbon group, etc.; or a salt thereof.Type: GrantFiled: December 26, 2002Date of Patent: March 24, 2009Assignee: Takeda Chemical Industries Ltd.Inventors: Nobuo Cho, Kazuyoshi Aso, Satoshi Endo, Naoyuki Kanzaki, Satoshi Sasaki
-
Publication number: 20070179165Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W—Ar??(I) wherein, A is a group represented by the formula (A1) or (A2): (wherein, ring Aa is a 5- or 6-membered ring which may be further substituted; ring Ab is a 5- or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, —O—, —S—, etc.; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; is a single or double bond); W is a bond, optionally substituted methylene, optionally substituted imino, —O—, —S—, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.Type: ApplicationFiled: April 6, 2005Publication date: August 2, 2007Inventors: Albert Gyorkos, Christopher Corrette, Suk Cho, Timothy Turner, Kazuyoshi Aso, Masakuni Kori, Michiyo Mochizuki, Kevin Condroski, Christopher Siedem, Steven Boyd
-
Publication number: 20070135452Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A?): wherein X is a carbon and X1 is an oxygen, a sulfur or —NR5—, or formula (A?): wherein X is a nitrogen and R6 is an optionally substituted hydrocarbyl, R1 is an amino substituted by two optionally substituted hydrocarbyl groups, R2 is an phenyl, Y1 is CR3a or a nitrogen, y2 is CR3b or a nitrogen and Y3 is CR3c or a nitrogen, provided that one or less of Y1, Y2, and Y3 is nitrogen, W is a bond, —(CH2)n-, and Z is a bond, —NR4—, etc.; or a salt thereof or a prodrug thereof.Type: ApplicationFiled: October 27, 2004Publication date: June 14, 2007Inventors: Albert Gyorkos, Christopher Corrette, Suk Cho, Timothy Turner, Scott Pratt, Kazuyoshi Aso, Masakuni Kori, Michiyo Gyoten
-
Patent number: 7229986Abstract: A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.Type: GrantFiled: May 15, 2001Date of Patent: June 12, 2007Assignee: Takeda Pharmaceutical Company Ltd.Inventors: Yuji Ishihara, Jun Terauchi, Nobuhiro Suzuki, Shiro Takekawa, Kazuyoshi Aso
-
Patent number: 7160887Abstract: Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents —CO—, —CON(Ra)—, COO—, N(Ra)CON(Rb)—, —N(Ra)COO—, —N(Ra)SO2—, N(Ra)—, —O—, —S—, —SO— or —SO2— (in which Ra and Rb each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from; (i) a C1-6 alkyl group, (ii) a halogeno-C1-6 alkyl group, (iii) a phenyl group, (iv) a benzyl group, (v) an optionally-substituted amino group, (vi) an optionallyType: GrantFiled: October 19, 1999Date of Patent: January 9, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Satoru Oi, Nobuhiro Suzuki, Kazuyoshi Aso, Yoshihiro Banno
-
Patent number: 7091247Abstract: A novel biphenyl compound having GPR 14 antagonistic activity. It is a compound represented by the formula (I): wherein R1 represents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc., R2 and R3 each represents a hydrocarbon group, etc.; and rings B and C each represents an optionally further substituted benzene ring, or a salt thereof.Type: GrantFiled: June 28, 2001Date of Patent: August 15, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Naoki Tarui, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Tetsuo Miwa, Shiro Takekawa
-
Publication number: 20050096359Abstract: The present invention provides a compound having melanocortin receptor agonist activity or antagonist activity, which is a novel biaryl compound represented by the formula (I): wherein ring A and ring B are optionally further substituted 6-membered aromatic rings; X is —CONR4—, —SO2NR4—, —CH2NR4— (R4 is a hydrogen atom, an optionally substituted hydrocarbon group, etc.), etc.; Y is a spacer having 1 to 12 atoms, etc.; Z is —CONR6—, —CO— (R6 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), etc.; R1 is an optionally substituted amino group, etc.; R2 is an optionally substituted hydrocarbon group, etc.; R3 is an optionally substituted hydrocarbon group, etc.; and R5 is an optionally substituted hydrocarbon group, etc.; or a salt thereof.Type: ApplicationFiled: December 26, 2002Publication date: May 5, 2005Inventors: Nobuo Cho, Kazuyoshi Aso, Satoshi Endo, Naoyuki Kanzaki, Satoshi Sasaki
-
Publication number: 20040106792Abstract: A novel biphenyl compound having GPR 14 antagonistic activity.Type: ApplicationFiled: December 20, 2002Publication date: June 3, 2004Inventors: Naoki Tauri, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Tetsuo Miwa, Shiro Takekawa
-
Publication number: 20040063699Abstract: A novel GPR14 antagonist. The GPR14 antagonist comprises a compound represented by the formula (I) or a salt thereof wherein Ar represents optionally substituted aryl; X represents a spacer; n is an integer of 1 to 10; R represents an optionally substituted hydrocarbon group, etc., provided that R may be bonded to Ar, etc. to form a ring; and Y represents optionally substituted amino, etc.Type: ApplicationFiled: January 2, 2003Publication date: April 1, 2004Inventors: Naoki Tarui, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Yuji Ishihara
-
Publication number: 20030158177Abstract: A melanin-concentrating hormone antagonist comprising a compound of the formula: 1Type: ApplicationFiled: November 12, 2002Publication date: August 21, 2003Inventors: Yuji Ishihara, Jun Terauchi, Nobuhiro Suzuki, Shiro Takekawa, Kazuyoshi Aso
-
Patent number: 6117566Abstract: A lead frame material, which can be provided with an etching stop layer without requiring a troublesome process such as vapor deposition and has an excellent heat-resistance, is obtained by forming a nickel-phosphorus alloy layer (B) of 1.6 to 10 .mu.m thickness containing 0.3 to 1.0 wt % of phosphorus on a copper or copper alloy layer (A) of 35 to 300 .mu.m thickness, and forming an optional copper layer (C) of 0.2 to 30 .mu.m thickness on the nickel-phosphorus alloy layer (B).Type: GrantFiled: July 21, 1999Date of Patent: September 12, 2000Assignees: Nippon Denkai, Ltd., North CorporationInventors: Tatsunori Matsumoto, Masami Noguchi, Kazuyoshi Aso
-
Patent number: 5712047Abstract: A copper foil for a printed wiring board which has a carbon-containing copper-zinc coating comprising 40 to 90 atomic % of copper, 5 to 50 atomic % of zinc and 0.1 to 20 atomic % of carbon is produced by dipping a copper foil in a non-cyanide copper-zinc electroplating bath containing a copper salt, a zinc salt, a hydroxycarboxylic acid or a salt thereof, an aliphatic dicarboxylic acid or a salt thereof and a thiocyanic acid or a salt thereof, and carrying out electrolysis in the non-cyanide copper-zinc electroplating bath using the copper foil as a cathode to form on at least one surface of the copper foil a carbon-containing copper-zinc coating.Type: GrantFiled: March 11, 1996Date of Patent: January 27, 1998Assignee: Nippon Denkai, Ltd.Inventors: Kazuyoshi Aso, Masami Noguchi, Katsumi Kobayashi, Takeshi Yamagishi
-
Patent number: 5534128Abstract: A copper foil for a printed wiring board which has a carbon-containing copper-zinc coating comprising 40 to 90 atomic % of copper, 5 to 50 atomic % of zinc and 0.1 to 20 atomic % of carbon is produced by dipping a copper foil in a non-cyanide copper-zinc electroplating bath containing a copper salt, a zinc salt, a hydroxycarboxylic acid or a salt thereof, an aliphatic dicarboxylic acid or a salt thereof and a thiocyanic acid or a salt thereof, and carrying out electrolysis in the non-cyanide copper-zinc electroplating bath using the copper foil as a cathode to form on at least one surface of the copper foil a carbon-containing copper-zinc coating.Type: GrantFiled: February 24, 1995Date of Patent: July 9, 1996Assignee: Nippon Denkai, Ltd.Inventors: Kazuyoshi Aso, Masami Noguchi, Katsumi Kobayashi, Takeshi Yamagishi
-
Patent number: 5459129Abstract: A novel compound of the formula: ##STR1## wherein a ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent cyclic or chain group; either one of Q.sup.1 and Q.sup.2 stands for N and the other stands for N or CH; X stands for an amino group, hydroxyl group or mercapto group; Y stands for H, halogen atom or a group bonded through C, N, 0 or S; Z stands for a straight-chain divalent group having 2 to 5 atoms constituted of optionally substituted carbon atoms or constituted of optionally substituted carbon atoms and one optionally substituted hetero-atom; COOR.sup.1 and COOR.sup.2 independently stand for an optionally esterified carboxyl group; n denotes an integer of 2 to 6; and R.sup.1 may be different in each of n repeating units, or their salts and it is useful as a therapeutic drug for tumor in mammals.Type: GrantFiled: August 27, 1993Date of Patent: October 17, 1995Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroshi Akimoto, Kazuyoshi Aso, Koichiro Ootsu
-
Patent number: 5268362Abstract: A novel compound of the formula: ##STR1## wherein a ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent cyclic or chain group; either one of Q.sup.1 and Q.sup.2 stands for N and the other stands for N or CH; X stands for an amino group, hydroxyl group or mercapto group; Y stands for H, halogen atom or a group bonded through C, N, O or S; Z stands for a straight-chain divalent group having 2 to 5 atoms constituted of optionally substituted carbon atoms or constituted of optionally substituted carbon atoms and one optionally substituted hetero-atom; COOR.sup.1 and COOR.sup.2 independently stand for an optionally esterified carboxyl group; n denotes an integer of 2 to 6; and R.sup.1 may be different in each of n repeating units, or their salts and it is useful as a therapeutic drug for tumor in mammals.Type: GrantFiled: December 16, 1991Date of Patent: December 7, 1993Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroshi Akimoto, Kazuyoshi Aso, Koichiro Ootsu